We gathered some of the best bio-artificial intelligence specialists in the world. By focusing exclusively on the entire genome (we don’t use gene panels) as a rich source of information – we extract the key data specifically for you.
We provide a range of services related to personalized genome analysis for patients with rare or cancer disease.
In the past, the decision to use a specific drug or treatment, depended on relatively limited information, often influenced by the subjective judgement of the individual physician.
Today, Artificial Intelligence allows us to analyze vast amount of data and accurately identify factors, which can be decisive in determining response to certain drugs.
That allows doctors to select the most beneficial treatment options for the patient. Best decisions are made by combining information from the patient’s genomic signatures, disease history and present health.
EMQN was established in order to spread QA standards in the field of genetic and molecular research across Europe. The network strives to make diagnostic molecular genetic laboratory tests accurate, reliable and comparable regardless of where they are produced.
We participate in EQA pilot WGS data analysis schemes run by EMQN since 2019, for NGS-based germline and for NGA-based somatic testing.
Whole genome sequencing (WGS)
Comprehensive view of the unique pathogenic variants and structural alterations in cancer genome with full analysis of oncogenes, tumour suppressors, and risk factors.
We are an example of how humans and technology can work together. AI is a tool which can help in areas where human capabilities remain limited.
We have all the necessary infrastructure to provide the highest quality services.
Winning team on board
Our staff consists of people from leading world universities and research centers
If you are interested in our activities, products or services we’ll be happy to help.